Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis

https://doi.org/10.4081/monaldi.2008.401

Authors

  • C. Incorvaia | cristoforo.incorvaia@fastwebnet.it Pulmonary Rehabilitation Dept., ICP Hospital, Milan, Italy.
  • C. Pravettoni Pulmonary Rehabilitation Dept., ICP Hospital, Milan, Italy.
  • M. Mauro Allergy Dept., Sant’Anna Hospital, Como, Italy.
  • M.-R. Yacoub Allergy and Rheumatology Unit, IRCCS San Raffaele Hospital, Milan, Italy.
  • F. Tarantini Respiratory Clinical Research, Novartis Farma S.p.A., Origgio, Italy.
  • G.G. Riario-Sforza Pulmonary Rehabilitation Dept., ICP Hospital, Milan, Italy.

Abstract

The anti-IgE antibody omalizumab is currently indicated in severe asthma not controlled by standard drug therapy. Recently, new indications for omalizumab were suggested, which include atopic dermatitis (AD), a skin disorder characterized by elevated levels of IgE. We report the case of a 39-year old woman with severe asthma and severe AD, both resistant to conventional drug treatment. The patient had a IgE level of 1304 kU/L, which exceeded the recommended maximum level for treating asthma with omalizumab (stated in 700 Ku/L) but was far lower than previously reported in cases of AD treated with anti-IgE. The treatment consisted of a dose of omalizumab 375 mg every two weeks, and induced a rapid improvement of asthma, with no need of other drugs after three months, along with a progressive decline of severity of AD, which after five months was completely cured. These findings suggest the usefulness of omalizumab in patients with concomitant severe asthma and AD, also considering the pharmaco-economic balance obtained by withdrawing the multiple drugs used to treat both diseases.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Downloads

Published
2016-01-26
Info
Issue
Section
Case Reports
Keywords:
Anti-IgE, Omalizumab, Severe asthma, Atopic dermatitis
Statistics
  • Abstract views: 724

  • PDF: 470
How to Cite
Incorvaia, C., C. Pravettoni, M. Mauro, M.-R. Yacoub, F. Tarantini, and G.G. Riario-Sforza. 2016. “Effectiveness of Omalizumab in a Patient With Severe Asthma and Atopic Dermatitis”. Monaldi Archives for Chest Disease 69 (2). https://doi.org/10.4081/monaldi.2008.401.

Most read articles by the same author(s)